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Abstract
Background: Human adipose-derived mesenchymal stem cells (haMSCs) have shown efficacy in treating osteoarthritis
(OA) both preclinically and clinically via intra-articular (IA) injection. However, understanding the mode of action of the
cell therapy has been limited by cell tracking capability and correlation between the pharmacokinetics of the injected
cells and the intended pharmacodynamics effect. This study aims to explore methodology and to understand in vivo
biodistribution of clinical-grade haMSCs labeled with fluorescent dye and injected into an immunocompetent OA rat
model.
Methods: haMSCs labeled with fluorescent dye were investigated for their proliferation and differentiation capabilities.
Labeled cells were used to establish detection threshold of a noninvasive biofluorescent imaging system before the
cells (2.5 × 106) were injected into a conventional rat OA model induced by medial meniscectomy for 8 weeks. We
attempted to reveal the existence of labeled cells in vivo by imaging and a molecular biomarker approach, and to
correlate with the in vivo efficacy and physical presence over a follow-up period up to 10 weeks.
Results: In vitro proliferation and differentiation of haMSCs were not affected by the labeling of DiD dye. Detection
thresholds of the labeled cells in vitro and in vivo were determined to be 104 and 105 cells, respectively. When
2.5 × 106 haMSCs were injected into the joints of a rat OA model, fluorescent signals (or >105 cells) lasted for about
10 weeks in the surgical knee joint at the same time as efficacy was observed. Signals in nonsurgical rats only lasted
for 4 weeks. The human MSCs were shown to engraft to the rat joint tissues and were proliferative. Human FOXP2
gene was only detected in the knee joint tissue, suggesting limited biodistribution locally to the joints.
Conclusions: The current study represents the first attempt to correlate cell therapy efficacy on OA with the physical
presence of the injected haMSCs in the OA model, and demonstrates that human adipose-derived mesenchymal
stem cells persisted for 10 weeks locally in the rat joint, coinciding with the efficacy observed. It is postulated that
persistence and/or proliferation of the haMSCs in the joint is required in order to exert their functions on promoting
joint regeneration and/or cartilage protection, further supporting the safety and feasibility of IA injection of MSCs for
the treatment of OA patients.
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Background
In the past decade, the therapeutic potential of mesenchy-
mal stem cells (MSCs) for the treatment of osteoarthritis
(OA) has been explored preclinically [1, 2]. The successful
preclinical studies have led to the initiation of a number of
clinical trials. In a randomized, double-blinded, controlled
clinical trial [3], 24 % of a total of 55 patients who under-
went a partial medial meniscectomy followed by intra-
articular (IA) injection with 5–15 × 107 allogeneic bone
marrow-derived MSCs achieved a 15 % increase in the
meniscal volume determined by magnetic resonance
imaging (MRI) at the 2-year follow-up, suggesting evi-
dence of meniscus regeneration after MSC treatment.
Another proof-of-concept clinical trial in which OA pa-
tients (n = 9) treated with IA injection of 10 × 107
adipose-derived autologous MSCs demonstrated im-
proved Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) scores and regener-
ation of hyaline-like cartilage in the affected joint [4].
Recently, allogeneic bone marrow-derived MSCs were
also used in an OA clinical trial. In a randomized con-
trolled trial, 10 × 107 allogeneic MSCs were delivered
into OA knee joint of 15 patients. After 12 months of
follow-up, both the visual analogue scale (VAS) and
WOMAC pain scores, and also the WOMAC general
and Lequesne scores were significantly improved when
compared to the hyaluronic acid (HA) delivery control
group [5]. All these clinical data indicated that MSC via
IA injection may serve as a new therapeutic strategy
and technology for OA treatment.
From a pharmacological perspective, it is very import-
ant to investigate the pharmacokinetics (PK)/pharma-
codynamics (PD) relationship of an active therapy.
Although MSC is not a traditional drug, and preclinical
data generated from MSC may not always be as in-
structive as for drug molecules, investigating the PK/
PD of MSC is essential to understand the dosing,
scheduling, and mode of action (MOA) in vivo. The
successful product launch of MSC as a “drug” and its
translation to the clinical application for OA treatment
is currently obstructed partly because of two reasons:
1) lack of specific MOA biomarkers; and 2) lack of a
pharmacokinetic tool for measuring living cells due to
the difficulty of in vivo cell fate tracking. Up to now,
most preclinical studies on MSC PK/PD after IA injec-
tion for OA treatment have been performed by ex vivo
histological analysis of β-galactosidase expression or
green fluorescent protein (GFP) in the grafted cells.
Horie et al. [6] used transgenic rats expressing dual lu-
ciferase (Luc) and LacZ to ascertain the Luc/LacZ+
synovium-derived MSCs. Twelve weeks after IA injec-
tion, regenerated menisci expressing type II collagen
were found to be LacZ+, and the LacZ+ MSCs were not
discovered in any other organs except for articular
synovium. Murphy et al. [1] found that, after IA injec-
tion of retroviral GFP-transduced MSCs into a caprine
OA model, GFP-MSCs were presented and integrated
into the cell layers lining joint structures such as the
meniscus, synovial capsule, and periosteum on the
medial condyle 1 week after injection. Moreover, an-
other study also found that human MSCs labeled with
carboxyfluorescein diacetate succinimidyl ester (CFDA-
SE) were distinguished within the cartilage at 1 week
post-transplantation in a guinea pig spontaneous OA
model, and labeled cells gradually disappeared from the
cartilage at 3–5 weeks post-transplantation [7]. How-
ever, disadvantages of ex vivo histology analyses are ob-
vious since the monitoring of cell fate is noncontinuous
and sections of joint samples may miss some meaning-
ful signals, especially when labeled MSCs scattered into
different tissues within a joint. Furthermore, ex vivo
histology analyses find it difficult to provide overall in-
formation on MSCs migrating into other distant organs
in order to eliminate safety concerns for MSCs via local
injection. All these shortcomings prompted development
of new methods to monitor MSC PK/PD. Recently, the
development of in vivo noninvasive imaging methodolo-
gies has provided one kind of tool to examine delivery,
grafting, distribution, and survival of MSCs after IA injec-
tion [6, 8, 9]. However, detection sensitivity or threshold
of MSC numbers that could be detected in vivo has not
been fully investigated in these noninvasive imaging
methodologies.
DiD is an analog of DiI (dialkylcarbocyanines) with
markedly red-shifted fluorescence excitation (644 nm)
and emission (665 nm) spectra. This characteristic is
useful in avoiding autofluorescence and phototoxic ef-
fects as well as offering two-color labeling [10]. Recently,
DiI-labeled bone marrow stromal cells were transplanted
subcutaneously in nude mice to explore the in vivo
traceability, and data demonstrated that DiI fluorescent
signals could last at least 6 weeks after transplantation
[11]. Here, we investigated the persistence and biodistri-
bution of DiD-labeled human adipose-derived MSCs
(haMSCs) after IA injection in an immunocompetent rat
OA model in order to systematically understand the
mechanism of MSCs in treating OA. The extended ob-
servations of human cell engraftment, biodistribution,
and proliferation were reported over time in the animal
model, which correlated with efficacy, and supported
further development of the technology for OA therapy.
Methods
DiD labeling of haMSC and characterization by flow
cytometry
haMSC isolation was described previously [2]. haMSC
(1 × 106; passage 3) were incubated with 10 μM DiD fluor-
escent dye (Life Technologies & Molecular Probes, USA)
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for 50 min at 37 °C according to the manufacturer’s in-
structions. Features of haMSCs labeled with or without
DiD were analyzed using human MSC analysis kit (BD
Biosciences, USA). hMSC Positive Cocktail (CD90 FITC,
CD105 PerCP-Cy5.5 and CD73 APC) and PE hMSC
Negative Cocktail (CD34, CD11b, CD19, CD45, HLA-DR)
in the kit were used, while CD73 was excluded as the
emission spectra of APC overlapped with that of DiD.
hMSC Positive Isotype Control Cocktail (mIgG1κ FITC,
mIgG1 κ PerCP-Cy5.5, and mIgG1 κ APC) and PE hMSC
Negative Isotype Control Cocktail in the kit (mIgG1 κ PE
and mIgG2a κ PE) were also included as an isotype con-
trol. Cell fluorescence was evaluated by flow cytometry in
a FACS Calibur instrument and data were analyzed by
CellQuest software (Becton Dickinson).
Cell proliferation and differentiation assay
Proliferation of DiD-labeled or unlabeled cells was mea-
sured using the Cell Counting Kit-8 (Dojindo Molecular
Technologies, USA). Differentiation of DiD-haMSCs was
performed as previously reported [2]. Briefly, for adipo-
genic and osteogenic differentiation, cells were seeded and
grown in StemPro® adipogenesis differentiation medium
and StemPro® osteogenesis differentiation medium (Gibco,
USA) for 3 weeks, respectively. For chondrogenic differen-
tiation, micromass culture was used and cells were cul-
tured in StemPro® chondrogenesis differentiation medium
(Gibco, USA) for 4 weeks. The differentiation media were
re-fed every 3 days. Subsequently, Oil Red O staining, Ali-
zarin Red S staining, and Alcian Blue staining were per-
formed to visualize the lipid droplet, calcium deposition,
and cartilage, respectively. Cells were harvested at the end
point of tri-lineage differentiation for real time polymerase
chain reaction (PCR) to assess the specific gene expression
of ADIPONECTIN (5′-CGTGATGGCAGAGATGGCA
CT-3′ for forward and 5′-GCGAATGGGTACATTGGG
AACAG-3′ for reverse), OSTEOCALCIN (5′-TCCAAGC
AGGAGGGCAATAAG-3′ for forward and 5′-GCGTT
TGTAGGCGGTCTTCAAG-3′ for reverse), and COLLA-
GEN TYPE 2 ALPHA 1 (COL2α1) (5′-TCGCACTTGCC
AAGACCTGAA-3′ for forward and 5′-GGTCTCTCCA
AACCAGATGTG-3′ for reverse) associated with adipo-
genesis, osteogenesis, and chondrogenesis, respectively.
In vitro and in vivo biofluorescent imaging
To establish the in vitro detection threshold, 100 μL
phosphate-buffered saline (PBS) suspension containing
different doses of DiD-haMSCs (106, 105, 104, 103, and 0
cells) were imaged by a scan of pre-warmed (37 °C) IVIS
Spectrum (PerkinElmer, USA). In vivo detection sensitiv-
ity was explored by scanning nonsurgery rats immedi-
ately after IA injection with DiD-haMSCs at the same
dosages (106, 105, 104, 103, and 0 cells in 100 μL PBS, re-
spectively) as used in the in vitro study. Before imaging,
the rats were anesthetized by isoflurane, and hairs were
removed to reduce autofluorescence. The wavelengths of
absorption and excitation were set up at 640 nm and
668 nm, respectively. The longitudinal changes in fluor-
escent intensity were obtained every week postinjection.
Data were analyzed using the Living Image software
(PerkinElmer, USA) to evaluate the average signal inten-
sity of regions of interest (ROI). The lowest signal was
adjusted to the level of autofluorescence background.
Animal model and study design
Male Sprague-Dawley rats (250–350 g, Slac Laboratory
Animal, China) were used (n = 18) in all of the experi-
ments described, and were divided randomly into three
groups according to the subsequent IA injections which
they received: the nonsurgery group (n = 6), and the sur-
gery group (n = 12)—itself divided into two subgroups:
the free DiD group as a control (n = 6) and the DiD-
haMSC group (n = 6). Experimental protocols were ap-
proved by the Ethical Committee of National Engineer-
ing Research Center of Tissue Engineering of China. OA
was induced by medial meniscectomy of the right knee
according to previous methods under general anesthesia
and sterile conditions [12]. Eight weeks after surgery,
2.5 × 106 DiD-haMSCs suspended in 100 μL PBS were
injected into the right knee joint of OA rats with 26-
gauge needles while the same amount of DiD-free parti-
cles and DiD-haMSCs were introduced into the right
knee joint of OA rats and nonsurgery rats as control
groups, respectively.
Quantitative real-time PCR
At 14 days and 70 days postinjection, rats were sacrificed
and half of the heart, liver, spleen, lung, kidney, brain,
muscle adjacent to the joint, and the whole injected knee
joint were collected and dissociated using an Ultra-Turrax
T-50 homogenizer. DNA of the samples was isolated from
200 μL of tissue suspension using DNeasy Blood and Tis-
sue kit (Qiagen, USA) and quantified using NanoDrop
spectrophotometer (Labtech, USA). Real-time PCR was
conducted to measure the level of human-specific FOXP2
gene from a 33-ng DNA specimen in 10 μL PCR reagent
mixture containing 200 nM primers and 200 nM probe.
The primers and probe were as follows: 5-TGGTAGT
CTGGAACACCGTAAGAGT-3 (forward); 5-CATATGG
CAGGCTTTAGGTACCC-3 (reverse) for human FOXP2;
5-FAM-CTGGTGGGCTAAAAGGAAGAAAGAGGTC-
TAMRA-3 (probe). PCR conditions were as follows: 95 °C
for 5 min, followed by 40 cycles at 95 °C for 5 s, and then
60 °C for 30 s. A standard curve was generated by serial
dilution of human genomic DNA from haMSCs into
DNA from rat adipose-derived mesenchymal stem cells
(raMSCs) (the total DNA amount was kept constant at
33 ng; Table 1). According to the standard curve, the
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percentage of human DNA in 33 ng total DNA from each
organ or tissue was calculated.
Histological assessment
At 70 days postinjection, distal femurs and proximal tibias
were excised and fixed in 4 % paraformaldehyde and
decalcified in EDTA-buffered saline solution (pH 7.4,
0.25 mol/L). To assess haMSC localization and prolifera-
tion, paraffin-embedded serial sections were used for im-
munostaining using monoclonal antihuman mitochondria
antibody (Millipore; 1:80) and monoclonal antihuman
ki67 antibody (Abcam; 1:100). Human skin tissue and hu-
man hepatocellular carcinoma cell line HepG2 were used
as controls, respectively. To assess haMSC efficacy, the
specimens were paraffin embedded and sectioned for
hematoxylin/eosin (HE) and Safranin-O/Fast Green stain-
ing. Evaluations of general morphology and proteoglycans
were performed by two blinded researchers unaware of
the treatment, and scored according to the Modified
O’Driscoll grading system [13]. Furthermore, quantitative
assessment of cartilage thickness (CT) was carried out ac-
cording to a previous investigation [14].
Statistical analysis
Statistical analysis was conducted with GraphPad Prism
(version 6.0). Numerical results are presented as the
mean ± SEM. One-way analysis of variance was applied
to determine the difference of the optical density (OD)
value, DNA expression, and signal intensity in various
dosages, the Mann-Whitney U test was used to compare
groups at each time point in the tracking image. P values
<0.05 were considered statistically significant.
Results
Characteristics and viability of haMSCs by DiD labeling
remained stable in vitro
In order to know the labeling efficiency, haMSCs isolated
from a donor via lipoaspirates and cultured to passage 4
were stained with 10 μM DiD solutions. We found that
nearly all haMSCs were DiD-positive (Fig. 1a) consistent
with previous investigation [11]. For the next step, we
wanted to know if DiD labeling changed haMSC charac-
teristics or not. By using flow cytometry we found that
stemness of haMSCs remained after DiD labeling. Un-
labeled and labeled haMSCs both were positive for CD105
(90 % and 98.9 %, respectively) and CD90 (97.6 % and
98.4 %, respectively), the main cell surface markers for
MSCs. In addition, unlabeled and labeled haMSCs were
negative for CD34, CD11b, CD19, CD45, and HLA-DR
cocktail (1.47 % and 0.405 %, respectively), which are
nonMSC markers as defined by the International Society
for Cell Therapy (Fig. 1b). CCK8 assay confirmed no sig-
nificant variation in proliferation capacity of labeled
haMSCs at days 1, 3, 5, 7, and 9 compared with unlabeled
haMSCs, indicating that DiD labeling produced no alter-
ation on haMSC proliferation (Fig. 1c).
DiD labeling displayed no influence on haMSC stemness
in vitro
Since the characterization and proliferation of the DiD-
labeled haMSCs remained unaltered, we wanted to know
whether DiD labeling changed the differentiation capabil-
ity of haMSCs. In vitro differentiation studies on the
osteoblast, adipocyte, and chondrocyte cell lineages were
carried out to compare the multipotency of unlabeled and
labeled haMSCs, respectively. For osteoblast differenti-
ation, calcium deposition and Alizarin Red staining could
be observed in DiD-labeled and unlabeled haMSCs cul-
tured in the differentiation media containing ascorbic acid
and β-glycerol phosphate, while no mineralization was de-
tected when haMSCs were grown under nonosteogenic
conditions (Fig. 2a). Real-time PCR was carried out on day
21 of osteoblast differentiation (Fig. 2b). OSTEOCALCIN
gene expression was substantially upregulated during dif-
ferentiation. For adipocyte differentiation, lipid droplets
could be identified by Oil Red O staining while labeled
haMSCs grown in the absence of adipogenic inducers ex-
hibited no lipid droplets (Fig. 2a). The adipogenic marker
ADIPONECTIN was considerably upregulated during dif-
ferentiation (Fig. 2b). Although DiD-labeled haMSCs have
a slight decrease in ADIPONECTIN expression during
adipogenesis compared to the unlabeled haMSCs, ADIPO-
NECTIN expression in DiD-haMSCs was still significantly
high upon adipogenesis induction. When labeled and un-
labeled haMSCs were differentiated under chondrogenic
conditions, regional condensations were formed and gly-
cosaminoglycan (GAG) production stained positive for
Alcian blue while only faint background Alcian blue stain-
ing was observed under control conditions (Fig. 2a), and
the cartilage specific COL2α1 was extensively upregulated
during chondrogenesis (Fig. 2b). Taken together, all these
in vitro differentiation studies provided evidence that DiD
labeling did not alter the stemness or differentiation prop-
erty of haMSCs.
Table 1 Human and rat DNA mix in quantitative real-time PCR
Total DNA in reaction Percentage of
human DNA (%)
Ct FOXP2
Human DNA (ng) Rat DNA (ng)
33 0 100 25.6700
6.6 26.4 20 28.3400
1.32 31.68 4 30.6300
0.264 32.736 0.8 33.1200
0.0528 32.9472 0.16 35.9300
0.01056 32.98944 0.032 38
0.002112 32.997888 0.0064 38
0 33 0 38
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Tracking sensitivity of the biofluorescent imaging system
was determined in vitro and in vivo
To evaluate the detection limit of optical imaging in vitro,
serial dilutions of DiD-labeled haMSCs (106, 105, 104, 103,
and 0 cells) in 100 μl PBS were placed in Eppendorf tubes
and scanned by the IVIS Spectrum system. Positive correl-
ation between fluorescent signals and labeled haMSC
numbers were then estimated. The tubes containing 106
and 105 labeled haMSCs demonstrated markedly strong
fluorescence while 104 labeled haMSCs displayed marginal
fluorescence that could be detected (Fig. 3a). The fluores-
cence signal reached an undetectable level in the 103 la-
beled haMSC tube, indicating that the in vitro detection
threshold of DiD-haMSCs by the IVIS Spectrum system
was between 104 and 103 cells (Fig. 3b). After in vitro de-
tection sensitivity was determined, the in vivo noninvasive
detection threshold was also explored by IA injection of
DiD-haMSCs (106, 105, 104, 103, and 0 cells) into the knee
Fig. 1 Characterization of DiD-labeled human adipose-derived mesenchymal stem cells (haMSCs) showing the labeling efficiency and unaltered
surface markers and proliferation in vitro. a The high efficiency of DiD labeling, comparing cells positive in the fluorescent image with those in
the bright field (scale bars = 50 μm). b After labeling, haMSCs were positive for CD90 and CD105, and negative for the cocktail including CD34,
CD11b, CD19, CD45, and HLA-DR, the same as the unlabeled haMSCs. c Cell viability assay by OD measurement with CCK8 kit confirmed no significant
variation in proliferation capacity of labeled haMSCs at days 1, 3, 5, 7, and 9 compared with unlabeled haMSCs (no statistical significance)
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joint of rats. Results revealed that remarkable fluorescent
signals were displayed in rats injected with 106 and 105
cells, while signals in rats injected with 104 cells were un-
detectable, suggesting that the in vivo detection threshold
of DiD-haMSCs by the IVIS Spectrum system was be-
tween 105 and 104 cells (Fig. 3c and d).
Signal of DiD-haMSCs resided in the knee joint
After the detection threshold has been determined, we ex-
plored the persistence of a therapeutic dose of DiD-
haMSCs in the knee joint. When DiD-haMSCs (2.5 × 106
cells) were injected into the right knee joint of normal rats
and OA rats, fluorescent signals remained relatively stable
in the surgery joints and became undetectable after 70 days
following injection, while in the nonsurgery joints the sig-
nal diminished rather quickly at day 28 (Fig. 4a). Quantita-
tive fluorescent intensity (n = 2) appeared to peak at
around day 7 in both the nonsurgery group and surgery
group, and then decreased as time went on. However, we
suppose that the fluctuation of fluorescence intensity was
caused by individual differences and edema created by the
invasive procedure (operation and injection) since the
cells may proliferate but the fluorescent dye cannot
(Fig. 4b).
Proliferative haMSCs engrafted into rat cartilage
To understand the fate of the DiD-labeled haMSCs in
vivo, we performed immunohistochemical (IHC) stain-
ing to visualize human cells in the rat joints. Using
monoclonal antihuman mitochondrial antibody, IHC
staining demonstrated that human mitochondrial sig-
nals were positive in the meniscus and cartilage in the
haMSC-treated group and negative in the free DiD
group (Fig. 5). In addition, using monoclonal antihu-
man Ki67 antibody, we visualized human cells undergo-
ing proliferation in the same vicinity to the region
where cells also display human mitochondrial identity
(Fig. 5). The positive signal for human mitochondria
and Ki67 lasted 10 weeks. These data suggested that
human MSCs were able to engraft to the meniscus and
cartilage in the rat joint, and proliferated in situ.
Fig. 2 DiD labeling had no influence on differentiation of human adipose-derived mesenchymal stem cells (haMSCs) in vitro. a Unlabeled and
labeled haMSCs differentiated similarly under osteogenic, adipogenic, and chondrogenic conditions, producing robust mineralized matrix-large lipid
droplets, and condensing chondrocytes detecting by Alizarin Red S staining, Oil Red O staining, and Alcian Blue staining, respectively. Differentiated
haMSCs retained the DiD label, as fluorescence was detected at the end of each differentiation (scale bar = 100 μm). b At the end of culturing, the
osteogenic, adipogenic, and chondrogenic gene markers, OSTEOCALCIN, ADIPONECTIN, and CAL2A1 in labeled haMSCs were upregulated during
osteogenesis, adipogenesis, and chondrogenesis, respectively. No significant difference was seen between the labeled and unlabeled haMSCs
for the differentiation potential, except for the adiponectin expression where labeled haMSCs showed slightly less expression than the
unlabeled cells. The P values were obtained using one-way ANOVA analysis of variance (*P < 0.05). Data were collected from three repetitions
(n = 3). ns nonsignificant
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Fig. 3 Determination of tracking sensitivity of biofluorescent imaging in vitro and in vivo. a Among the serial dilutions, 104 labeled haMSCs
displayed a marginal fluorescence signal that could be detected above the phosphate-buffered saline (PBS) background. b Quantification of the
fluorescence signal in a showing that the detection threshold in vitro is between 103 and 104 cells (107 and 108 photons/s/cm2). c Remarkable
fluorescent signals were displayed in rats injected with 106 and 105 cells, while signals of 104 cells were undetectable, suggesting that the in vivo
detection threshold of DiD-haMSCs was between 105 and 104 cells. d Quantification of the fluorescence signal in c showing that the detection
threshold in vivo is between 104 and 105 cells (8 × 107 and 5 × 108 photons/s/cm2). Data were representative of two repetitions (n = 2)
Fig. 4 Signal of DiD-haMSCs residing in the knee joint. a Detection of florescent imaging of representative rats in both nonsurgery and surgery
groups over time. When DiD-haMSCs (2.5 × 106 cells) were injected into the right knee joint of the nonsurgery rats (top panel) and surgery rats
(bottom panel), signals remained relatively stable in surgery joints and became undetectable after 70 days of injection while in the nonsurgery
joints the signal diminished rather quickly at day 28. b Quantitative fluorescent intensity of the nonsurgery and surgery groups. Data show that
the average (n = 2) fluorescent intensity appeared to fluctuate as time went on. Signals in the surgery group lasted much longer than in
nonsurgery group
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No broad organ biodistribution of haMSC by quantitative
real-time PCR
To further evaluate whether IA injected haMSCs could
migrate to distant organs, quantitative real-time PCR
detecting human FOXP2 gene was performed on days 14
and 70. In order to draw a standard curve, DNA from
haMSCs was mixed with rat genomic DNA in different
concentrations to mimic the real situation (Table 1). We
found that the detection threshold was 0.01056 ng hu-
man DNA mixed with 32.98944 ng rat DNA, totaling
33 ng DNA in the reaction system (Ct = 38 and reached
plateau), indicating 0.032 % human DNA as the lowest
amount that could be detected (Fig. 6). After knowing
the detection threshold and standard curve, DNA iso-
lated from the heart, liver, spleen, lung, kidney, brain,
and knee joint tissues of the haMSC-injected rats at day
14 and day 70 were subjected to quantitative PCR for
the human-specific FOXP2 gene. At each time point, the
gene could not be detected in any tissues except for joint
muscles, joint ligament, and joint meniscus. Among
joint muscles and ligament, human DNA accounted for
0.235 % and 0.035 % of the total DNA content, respect-
ively, in one of three rats sacrificed at 14 days postinjec-
tion; at 70 days post-transplantation, human DNA
accounted for 0.094 % of the total DNA content of the
meniscus in another rat; at both time points, human
DNA was not detected in any other organs tested in any
animals (Table 2). These results confirmed the in vivo
imaging data, indicating that haMSCs remained localized
after IA delivery in immunocompetent rats.
Therapeutic efficacy of IA injection of haMSCs
Since haMSCs after IA injection were mainly concen-
trated in the joint area, our next step was to try and
confirm the therapeutic efficacy at 70 days after the cell
therapy to collaborate the biodistribution findings. In
the normal group, HE staining showed that the surface
of the articular cartilage was smooth and intact while in
the DiD control group (surgery-induced OA without
cell treatment), articular cartilage exhibited rough bor-
ders. Safranin-O/Fast green staining clearly revealed the
progression of degenerative OA phenotypes in the free
DiD control group compared with the normal group by
increased type I collagen expression. In the group with
the DiD-haMSC treatment, the joints of affected animals
displayed a continuous cartilage surface with few fissures
(Fig. 7a), exhibiting decreased type I collagen expression
and increased proteoglycan expression (Fig. 7b). The
modified O’Driscoll histological score revealed that the
DiD-haMSC treatment showed significantly higher scores
Fig. 5 Proliferative human cells were detected in the rat knee joint tissues. a Human skin tissues were used for positive (with monoclonal
antihuman mitochondria antibody) and negative (IgG isotype) IHC staining controls. Positive signals were detected in both nonsurgery and
surgery groups with human adipose-derived mesenchymal stem cell (haMSC) treatment, but not in the free DiD group (no haMSC treatment).
The human cells were mainly detected in the rat meniscus and cartilage. b Human hepatocellular carcinoma cell line HepG2 were used for
positive and negative controls with regard to a monoclonal antihuman ki67 antibody IHC staining. Human cells undergoing proliferation were
detected in the positive control as well as in the joint tissues of the DiD-labeled haMSC treatment groups, but not in the free DiD group. Samples
of the surgery group (n = 2) and the nonsurgery group (n = 2) were both collected at the end of the experiments (day 70 and day 28), respectively
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or better tissue preservation compared to the DiD control
group (Fig. 7c). Cartilage thickness also increased signifi-
cantly in the DiD-haMSC treatment group compared with
the free DiD group (Fig. 7d). Taking all data together, it
was clear that DiD-labeled haMSCs were able to prevent
the cartilage degeneration in surgery-induced OA animal
models as seen in similar haMSC efficacy studies without
DiD labeling; therefore, the results of MSC persistence
and biodistribution from this study becomes very much
relevant to the mode of action and therapeutic effect of
haMSCs for OA treatment.
Discussion
A number of previous investigations have reported the
efficacy of IA administration of MSCs for the treatment
of OA [1, 15, 16]; however, the fate of injected MSCs
remains unknown and we do not know how long MSCs
have to be in the joint in order to see the efficacy. In our
study, we tried to understand the fate and biodistribu-
tion of the haMSCs in the context of efficacy. Our data
show that haMSCs can be found in the rat joints via
intra-articular injection for the duration of the efficacy
period, as long as 70 days. We have also found that the
MSCs have a higher homing tendency to the injured
joint than the normal joint (persisted longer). Our data
are consistent with the study in nonOA SCID mice [17].
However, SCID mice were immune-deficient lacking
both B and T lymphocytes [18] while most of the OA
patients in the clinic would have normal immune func-
tion. Thus, MSC biodistribution in immunocompetent
OA animal models is more relevant to the clinic. More-
over, the life span and migration rate of MSCs in OA
joints and normal joints may be different due to the OA
inflammatory microenvironment, and secretion of in-
flammatory factors may attract MSCs homing to and
staying in the injury area [19], which is supported by our
findings.
The 10-week persistence of the MSCs in the OA joint
coincides with the time for which we observed efficacy,
strongly suggesting that OA efficacy by MSCs requires
a persistent cell activity rather than transient activity.
The finding that xenogeneic haMSCs engrafted into rat
meniscus and cartilage but not into other distant or-
gans is very intriguing and provides direct evidence that
MSCs are most likely conducting or initiating homeo-
stasis and tissue regeneration locally rather than sys-
temically. Another important finding, which to our
knowledge is perhaps for the first time, is that antihu-
man ki67 signals have been found in rat meniscus and
cartilage confirming in vivo proliferation of those
injected haMSCs (Fig. 5). This supports the concept of
cell therapy as a living drug. Formerly, CFDA-SE-
labeled 7.0 × 106 human MSCs were injected into the
OA joint of immunocompetent Hartley strain guinea
pigs, and labeled cells could be detected by histology at
Fig. 6 Threshold of human DNA in rat tissue was determined by
quantitative real-time PCR using the human-specific FOXP2 gene
probe. DNA from haMSCs were mixed with rat genomic DNA in
different concentrations for quantitative PCR showing that 0.032 %
human DNA (0.01056 ng human DNA in a total of 33 ng DNA) is
the lowest amount detected before reaching the plateau
Table 2 Percentages of human DNA were detected in the indicated organs at the time point indicated
Heart Liver Spleen Lung Kidney Brain Knee joint
Muscle Meniscus Synovium Ligament Cartilage
14 days postinjection
Rat 1 – – – – – – 0.235 % – – – –
Rat 2 – – – – – – – – – 0.035 % –
Rat 3 – – – – – – – – – – –
70 days postinjection
Rat 4 – – – – – – – 0.094 % – – –
Rat 5 – – – – – – – – – – –
Rat 6 – – – – – – – – – – –
All samples were from osteoarthritis rats treated with human adipose-derived mesenchymal stem cells
– indicates under the detection limit
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least 5 weeks afterwards in the OA cartilage [7]. An-
other investigation also found that after injection of
1.0 × 106 GFP-transduced MSCs into caprine OA joints,
GFP-positive cells were identified primarily at the sur-
face of neomeniscal tissue 6 weeks after injection [1].
Nonetheless, our data not only provide data for the
lifespan of injected MSCs but also in vivo biodistribu-
tion, with the conclusion that MSCs injected via IA
remained localized and did not migrate to other distant
organs and sites at the detection level. Another point
provided by our study is that most of the previous in
vivo tracking studies only focused on the use of track-
ing methodology [6, 11, 17, 20]; however, investigation
of the tracking technology itself, especially the sensitiv-
ity or limitation of each methodology, has not been
fully explored. The present study focused not only on
the validity of biofluorescent imaging technology but
also on the sensitivity of the technology to understand
the underlying biology. We found that by using the
IVIS Spectrum system the detection threshold of DiD
labeling was 104 cells and 105 cells in vitro and in vivo,
respectively. Although the sensitivity could be further
improved, it is the first time that the number of MSCs
detected in the joints of OA animal models over time
has been revealed.
In the present study, we have also obtained biodistri-
bution data. The accurate and sensitive human FOXP2
sequence was used to quantify human DNA in the xeno
background and to avoid possible artifacts due to poten-
tial rat genome interference. FOXP2 was the first gene
that was determined to be related to development of
human speech and language [21]. Due to its high con-
servation, the FOXP2 gene was identified as a human-
specific reporter gene in human genomic DNA [22–24].
We found that after 14 days of administration, the hu-
man FOXP2 sequence could be detected in the joint
ligament and muscles, whereas after 70 days of injection
the human-specific FOXP2 sequence could be detected
in the meniscus of the joint in some of the animals. We
did not get these detection results consistently across all
three animals tested, partly because of the low amount
of human DNA present when considering the amount of
disparity in human cells in the animal organ tissues.
Human DNA had not been detected in the cartilage, but
IHC staining identified human signals in the cartilage
(Fig. 5). It is possible that human DNA was missed when
partial organ/tissue were grinded for DNA isolation. The
detection of human cells in only very limited and joint-
related organs and tissues actually suggests the validity
of the qualitative method.
There are still some limitations in this study. For ex-
ample, although rats were chosen for this study and
other OA preclinical experiments [6, 25], rats are not
upright walking animals and the anatomy of rat knee
joints is not close to those of humans. Furthermore, in
vivo kinetics of the IA injection of MSCs has been dem-
onstrated, but the sensitivity of biofluorescent imaging
needs further improvement if fewer than 104 cells need
to be detected. More sensitive technologies, such as
magnetic resonance imaging or radiolabeled MSCs,
should be investigated. Building on this study, it may be
possible to closely establish the PK/PD relationship with
more precise technologies and time points to elucidate
the mechanism and cell activity required for efficacy in
treating OA patients.
Conclusion
The current study demonstrated PK/PD of labeled haMSCs
after IA injection in an immunocompetent surgery-
induced OA rat model. We found that proliferation and
differentiation of haMSCs were not affected by the label-
ing with DiD dye, and the detection thresholds of the la-
beled cells in vitro and in vivo were determined to be 104
and 105 cells, respectively. Moreover, fluorescent signals in
OA rats lasted for about 10 weeks in the knee joint at the
same time as efficacy was observed. Furthermore, human-
specific markers could only be detected in the joint liga-
ment, meniscus, and muscles adjacent to the joint, not in
other distant organs. Although more sensitive methods
may need to be investigated, the current results suggest
(See figure on previous page.)
Fig. 7 Therapeutic efficacy of IA injection of human adipose-derived mesenchymal; stem cells (haMSCs) in the OA model. a In the normal group,
HE staining showed natural histology of joints with a thick layer of cartilage and subchondral bone, and chondrocytes in organized lacuna (top
panel, 4×, and lower panel, 20×). In contrast, the thickness of the cartilage and especially the subchondral bone in the surgery-induced groups
were significantly reduced, and chondrocytes appeared to be more disorganized. haMSC treatment restored the thickness of the cartilage and
subchondral bone (scale bar = 500 μm). Note that the meniscus in the surgery groups all displayed damage, confirming the successful surgery of
meniscectomy for the model creation. b Safranin-O/Fast green staining for proteoglycan (PG)/collagen content revealed the significant loss of PG
(red staining) and increase of fibrillated collagen (green staining), a characteristic of degenerative OA phenotypes in the DiD control group
compared with the normal group. Treatment with the DiD-haMSCs exhibited increased proteoglycan expression and decreased type I collagen
expression (scale bar = 500 μm), thus restoring the overall cartilage thickness. c Cartilage thickness measured by ImageJ software increased
significantly in the haMSC-treatment group compared with the DiD group. d The modified O’Driscoll histological score for morphology and
structure characteristics quantified the changes, and supported that haMSC treatment showed significant morphological and structural improvement
of cartilage. The P values were obtained using one-way ANOVA analysis of variance (**P < 0.01). All the experiments were repeated at least
two times (n = 3)
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that local persistence of adipose-derived human mesen-
chymal stem cells may be important for their functions on
promoting joint regeneration to be exerted, further sup-
porting the safety and feasibility of IA injection of MSCs
in the treatment of OA.
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